Improved tumor oxygenation & survival in glioblastoma patients who show increased blood perfusion after cediranib and

[D.ap]

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoRadiation


“Significance

This study demonstrates that antiangiogenic therapy increases tumor blood perfusion in a subset of newly diagnosed glioblastoma patients, and that it is these patients who survive longer when this expensive and potentially toxic therapy is combined with standard radiation and chemotherapy. This study provides fresh insights into the selection of glioblastoma patients most likely to benefit from antiangiogenic treatments.”


http://m.pnas.org/content/110/47/19059.full

[D.ap]

November 4, 2013

Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, Massachusetts General Hospital (MGH) researchers report, those for whom treatment with the anti-angiogenic drug cediranib rapidly 'normalized' abnormal blood vessels around their tumors and increased blood flow within tumors survived significantly longer than did patients in whom cediranib did not increase blood flow. The report appears in PNAS Early Edition.

https://m.medicalxpress.com/news/2013-1 ... drugs.html